FDA Approves 50% Efficacy for COVID-19 Vaccines

Scientists believe US FDA’s 50% efficacy guideline for approval of COVID-19 vaccines is appropriate.



The US Food and Drug Administration set forth new guidelines for future approval of COVID-19 vaccines, which say that such preventive products are required to decrease the severity of the disease by at least 50 percent.

The new FDA vaccine guidelines were released in the summer during a meeting where senators sought assurances from FDA Commissioner Stephen Hahn, National Institute of Allergy and Infectious Diseases Director Anthony Fauci, and other high-ranking health officials that the expedited approval process will not compromise the integrity of the final product.

“I want the American people to hear me when I say we will use the science and data from those trials and will ensure that our high levels of standards for safety and efficacy are met,” Hahn said during the briefing.

In May, President Donald Trump announced Operation Warp Speed a government initiative to hasten the development of a vaccine with a year. Typically vaccines take years to develop and pass all regulations to reach the market.

Gregory Poland, the director of the Mayo Vaccine Research Group, told Reuters the efficacy guidelines are standard compared to other vaccines. “They look pretty much like influenza vaccine guidelines,” Poland says. “I don’t think that’s a high bar. I think that’s a low to . . . appropriate bar for a first-generation COVID-19 vaccine.” Even the flu shot is effective in only 40 to 60% of the cases.

Peter Hotez, a vaccine expert at the Baylor College of Medicine, says, vaccine developers should aim for 70–75 percent efficacy.

In contrast, Stephen Ostroff, a former acting FDA commissioner, says the 50 percent figure is too high. Given that the virus “is rampaging through a lot of parts of the United States, I would certainly consider a vaccine with less than 50 percent efficacy,” he says.

COVID-19 Vaccine Coronavirus FDA Efficacy

Learn about various COVID-19 vaccine updates along with the latest coronavirus news here at leading CEO magazine, Industry Leaders. (FDA photo by Michael J. Ermarth)

Vaccines are viewed with much distrust in the United States, with many not believing in their efficacy, and others feel that the side-effects are deadly and cause more harm. Only 45 percent of Americans get the flu shot each year, The Hill reports, Doctors say at least 75 to 80% people need to be inoculated for the vaccine to be effective.

“It is a reality. A lack of trust in authority, a lack of trust in government, and a concern about vaccines in general,” Fauci said. “We need to engage the community by boots on the ground, and particularly those populations that have not always been treated fairly by the government—minority populations, African Americans, Latinx, and Native Americans.”

Clinical trials of coronavirus vaccines underway are assessing whether the vaccines can curtail the disease and by how much. Study results also may include additional information about how vaccinated people that contact the disease are able to fight it off.

Studies will give details on gender and age response to the vaccine and also the response of people with underlying conditions.

Availability of an FDA approved COVID-19 vaccine likely won’t mean an immediate end to the pandemic, experts say.

But they say even if the first batches are not fully effective against the disease, it makes sense to immunize as some resistance will be formed and also a booster can be taken at a later date or even a better vaccine shot that comes out later.

“I would feel much better knowing that I got vaccinated and have some levels of virus-neutralizing antibody in my system,” said vaccine researcher Dr Hotez. “Even if it’s not the best vaccine, it still could prevent me from going to the hospital or worse.”

Christy Gren
Christy Gren is an Industry Specialist Reporter at Industry Leaders Magazine she enjoys writing about Unicorns, Silicon Valley, Startups, Business Leaders and Innovators. Her articles provide an insight about the Power Players in the field of Technology, Auto, Manufacturing, and F&B.

Recent Posts

IPOs Stumbling in Face of High Valuations

IPOs Stumbling in Face of High Valuations

More than half of the companies that raised more than $1 billion for initial public offerings are now trading way below their listing price.
23 mins ago
Bay Area Businesses Brace for New COVID-19 Omicron Variant

Bay Area Businesses Brace for New COVID-19 Omicron Variant

San Francisco braces for the likely arrival of the new Covid-19 variant known as Omicron. The latest variant has a reproduction rate of two.
24 hours ago
Omicron Variant Pushes Markets into Panic Selling

Omicron Variant Pushes Markets into Panic Selling

Markets across the globe rush to safer havens as the resurgence of the Omicron variant spells fear of economic suffering due to potential lockdown orders.
1 day ago
Loeb’s Third Point rakes in $300m from Rivian’s IPO

Loeb’s Third Point rakes in $300m from Rivian’s IPO

Dan Loeb’s hedge fund Third Point made a profit of about $300 million from its stake in electric car maker Rivian’s blockbuster US IPO earlier this month.
3 days ago
Best Electric Bikes for Any Budget & Terrain (2022)

Best Electric Bikes for Any Budget & Terrain (2022)

Industry Leaders has curated details and insights on the five best electric bikes that will be available by 2022.
4 days ago
3 Invaluable Leadership Lessons from Jeff Bezos

3 Invaluable Leadership Lessons from Jeff Bezos

Jeff Bezos is an American entrepreneur with so much experience in leadership and business. We can learn a lot from the New Mexico-born billionaire.
4 days ago